Aptabio Therapeutics, Inc.
7
4
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
1 terminated/withdrawn out of 7 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
Role: lead
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
Role: lead
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Role: lead
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
Role: lead
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
Role: lead
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
Role: lead
Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers
Role: lead
All 7 trials loaded